BridgeMD
Etude de dose de l’acide tranexamique dans la prothèse totale de hanche pour réduire la perte d’hémoglobine post-opératoire. Etude de phase 2 randomisée en double aveugle monocentrique. Etude PRADO
EU CTIS ID: 2022-502532-38-01
What this study is testing
To evaluate of the dose-response relationship of intravenous intravenous tranexamic acid administration in the total hip prosthesis on the reduction of perioperative hemoglobin loss.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patient requiring primary hip arthroplasty (less than 3 months)
- Consent of the patient or a family member or the support person
You likely can't join if
- Contraindication to tranexamic acid
- Contraindication to apixaban
- Pregnancy
- Patient receiving a curative anticoagulating treatment in the preoperative period
- Bilateral or previous hip arthroplasty
- Hemorrhagic surgery less than 2 weeks old
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.